bayer:

Bayer initiates asundexian Phase III study program

BERLIN (Reuters) – Germany’s Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. The drug…
August 28, 2022

Bayer wins fourth Roundup weedkiller case in U.S

FRANKFURT – A U.S. jury found Bayer’s Roundup weedkiller did not cause an Oregon man’s cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial…
June 18, 2022